Retrophin Inc (NASDAQ:RTRX) rose 6% during mid-day trading on Friday . The stock traded as high as $12.86 and last traded at $12.85, approximately 368,447 shares changed hands during trading. A decline of 23% from the average daily volume of 481,191 shares. The stock had previously closed at $12.12.
Several equities analysts have commented on RTRX shares. William Blair reiterated a “buy” rating on shares of Retrophin in a research report on Friday, August 23rd. Jefferies Financial Group set a $33.00 target price on shares of Retrophin and gave the stock a “buy” rating in a research note on Friday, August 23rd. ValuEngine upgraded shares of Retrophin from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. BidaskClub upgraded shares of Retrophin from a “strong sell” rating to a “sell” rating in a research note on Thursday, October 31st. Finally, Zacks Investment Research upgraded shares of Retrophin from a “hold” rating to a “strong-buy” rating and set a $14.00 price target on the stock in a research note on Wednesday. One analyst has rated the stock with a sell rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $27.75.
The company has a market capitalization of $532.63 million, a PE ratio of -5.06 and a beta of 0.79. The company’s 50 day simple moving average is $11.72 and its 200 day simple moving average is $16.50. The company has a debt-to-equity ratio of 0.82, a current ratio of 5.00 and a quick ratio of 4.94.
Hedge funds have recently bought and sold shares of the business. Perceptive Advisors LLC raised its holdings in shares of Retrophin by 23.5% in the 2nd quarter. Perceptive Advisors LLC now owns 3,772,582 shares of the biopharmaceutical company’s stock worth $75,791,000 after buying an additional 717,875 shares in the last quarter. Vanguard Group Inc. increased its stake in Retrophin by 3.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,192,002 shares of the biopharmaceutical company’s stock valued at $44,036,000 after buying an additional 73,736 shares during the last quarter. Rock Springs Capital Management LP increased its stake in Retrophin by 14.5% in the 2nd quarter. Rock Springs Capital Management LP now owns 950,000 shares of the biopharmaceutical company’s stock valued at $19,086,000 after buying an additional 120,000 shares during the last quarter. D. E. Shaw & Co. Inc. increased its stake in Retrophin by 3.9% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 891,667 shares of the biopharmaceutical company’s stock valued at $17,914,000 after buying an additional 33,078 shares during the last quarter. Finally, Nuveen Asset Management LLC purchased a new stake in Retrophin in the 2nd quarter valued at about $14,273,000.
Retrophin Company Profile (NASDAQ:RTRX)
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
See Also: Yield Curve
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.